BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17420427)

  • 1. Older age and the response to and tolerability of antiretroviral therapy.
    Silverberg MJ; Leyden W; Horberg MA; DeLorenze GN; Klein D; Quesenberry CP
    Arch Intern Med; 2007 Apr; 167(7):684-91. PubMed ID: 17420427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
    Horberg MA; Hurley LB; Klein DB; Follansbee SE; Quesenberry C; Flamm JA; Green GM; Luu T
    Arch Surg; 2006 Dec; 141(12):1238-45. PubMed ID: 17178967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency.
    Micheloud D; Berenguer J; Bellón JM; Miralles P; Cosin J; de Quiros JC; Conde MS; Muñoz-Fernández MA; Resino S
    J Infect; 2008 Feb; 56(2):130-6. PubMed ID: 18192020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy.
    Brañas F; Berenguer J; Sánchez-Conde M; López-Bernaldo de Quirós JC; Miralles P; Cosín J; Serra JA
    Am J Med; 2008 Sep; 121(9):820-4. PubMed ID: 18724973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
    Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F;
    HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients.
    Amara S; Dezube BJ; Cooley TP; Pantanowitz L; Aboulafia DM
    Clin Infect Dis; 2006 Nov; 43(9):1198-205. PubMed ID: 17029142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Highly active antiretroviral therapy in HIV sero-positive children. Disease progression by baseline clinical, immunological and virological status].
    Rodríguez de Schiavi MS; Scrigni A; García Arrigoni P; Bologna R; Barboni G; Redondo J; Nastri M; Mecikovsky D; Cantisano C; Moreno R; Siciliani D; Lencina M; Luedicke N; Rezzónico G; Torolla JL; López Papucci S; Luis M; Libonati C; Gamba L; Barbarysky J; Pérez Hernández E; Zlatkes R
    Arch Argent Pediatr; 2009 Jun; 107(3):212-20. PubMed ID: 19543629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients.
    Orlando G; Meraviglia P; Cordier L; Meroni L; Landonio S; Giorgi R; Fasolo M; Faggion I; Riva A; Zambelli A; Beretta R; Gubertini G; Dedivitiis G; Jacchetti G; Cargnel A
    HIV Med; 2006 Nov; 7(8):549-57. PubMed ID: 17105515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
    Polesel J; Clifford GM; Rickenbach M; Dal Maso L; Battegay M; Bouchardy C; Furrer H; Hasse B; Levi F; Probst-Hensch NM; Schmid P; Franceschi S;
    AIDS; 2008 Jan; 22(2):301-6. PubMed ID: 18097233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Greater effect of highly active antiretroviral therapy on survival in people aged > or =50 years compared with younger people in an urban observational cohort.
    Perez JL; Moore RD
    Clin Infect Dis; 2003 Jan; 36(2):212-8. PubMed ID: 12522755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.